162 related articles for article (PubMed ID: 34678225)
1. Ubiquitin-specific proteases as therapeutic targets in paediatric primary bone tumours?
Mullard M; Lavaud M; Regnier L; Tesfaye R; Ory B; Rédini F; Verrecchia F
Biochem Pharmacol; 2021 Dec; 194():114797. PubMed ID: 34678225
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the Ubiquitin Specific Proteases USP43, USP41, USP27x and USP6 in Osteosarcoma Cell Lines: Inhibition of Osteosarcoma Tumor Growth and Lung Metastasis Development by the USP Antagonist PR619.
Lavaud M; Mullard M; Tesfaye R; Amiaud J; Legrand M; Danieau G; Brion R; Morice S; Regnier L; Dupuy M; Brounais-Le Royer B; Lamoureux F; Ory B; Rédini F; Verrecchia F
Cells; 2021 Aug; 10(9):. PubMed ID: 34571917
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy in the management of osteosarcoma and Ewing's sarcoma.
Schuetze SM
J Natl Compr Canc Netw; 2007 Apr; 5(4):449-55. PubMed ID: 17442235
[TBL] [Abstract][Full Text] [Related]
4. Paley's multiplier method does not accurately predict adult height in children with bone sarcoma.
Gilg MM; Wibmer C; Andreou D; Avian A; Sovinz P; Maurer-Ertl W; Tunn PU; Leithner A
Clin Orthop Relat Res; 2014 Aug; 472(8):2506-13. PubMed ID: 24777720
[TBL] [Abstract][Full Text] [Related]
5. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Antman K; Crowley J; Balcerzak SP; Kempf RA; Weiss RB; Clamon GH; Baker LH
Cancer; 1998 Apr; 82(7):1288-95. PubMed ID: 9529020
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
[TBL] [Abstract][Full Text] [Related]
7. Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors.
Chen S; Liu Y; Zhou H
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925279
[TBL] [Abstract][Full Text] [Related]
8. Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?
Serra M; Hattinger CM; Pasello M; Casotti C; Fantoni L; Riganti C; Manara MC
Cells; 2021 Sep; 10(9):. PubMed ID: 34572110
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
10. Conditional survival is greater than overall survival at diagnosis in patients with osteosarcoma and Ewing's sarcoma.
Miller BJ; Lynch CF; Buckwalter JA
Clin Orthop Relat Res; 2013 Nov; 471(11):3398-404. PubMed ID: 23821136
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES.1.
Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Oncol Rep; 2005 Feb; 13(2):253-7. PubMed ID: 15643507
[TBL] [Abstract][Full Text] [Related]
12. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
13. Second cancers in long-term survivors of Ewing's sarcoma.
Smith LM; Cox RS; Donaldson SS
Clin Orthop Relat Res; 1992 Jan; (274):275-81. PubMed ID: 1729013
[TBL] [Abstract][Full Text] [Related]
14. Osteoporosis in children and young adults: a late effect after chemotherapy for bone sarcoma.
Pirker-Frühauf UM; Friesenbichler J; Urban EC; Obermayer-Pietsch B; Leithner A
Clin Orthop Relat Res; 2012 Oct; 470(10):2874-85. PubMed ID: 22806259
[TBL] [Abstract][Full Text] [Related]
15. [Cytostatic treatment as supplement in osteosarcoma and Ewing's sarcoma. Preliminary communication (author's transl)].
Krizan Z; Makai F; Krizan I; Blasková L; Látal J; Majeský B
Acta Chir Orthop Traumatol Cech; 1979 Feb; 46(1):26-8. PubMed ID: 88152
[No Abstract] [Full Text] [Related]
16. The role of ubiquitin-specific peptidases in cancer progression.
Young MJ; Hsu KC; Lin TE; Chang WC; Hung JJ
J Biomed Sci; 2019 May; 26(1):42. PubMed ID: 31133011
[TBL] [Abstract][Full Text] [Related]
17. Ewing's sarcoma: standard and experimental treatment options.
Subbiah V; Anderson P; Lazar AJ; Burdett E; Raymond K; Ludwig JA
Curr Treat Options Oncol; 2009 Apr; 10(1-2):126-40. PubMed ID: 19533369
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
19. Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.
Sampson VB; Kamara DF; Kolb EA
Expert Opin Drug Discov; 2013 Oct; 8(10):1181-9. PubMed ID: 23844615
[TBL] [Abstract][Full Text] [Related]
20. Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells.
Lollini PL; Landuzzi L; Frabetti F; Rossi I; Nicoletti G; Scotlandi K; Serra M; Baldini N; De Giovanni C; Nanni P
Clin Cancer Res; 1998 Aug; 4(8):1843-9. PubMed ID: 9717810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
